

CLAIMS

1. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of non-infectious uveitis in a subject in need thereof, in combination with a corticosteroid or corticosteroid tapering, the pharmaceutical composition comprising an antibody that specifically binds IL-6 receptor,
- 5 wherein the subject has a vitreous haze (VH) level greater than or equal to 2 on the Miami 9 step scale or wherein the subject has a central retinal thickness (CRT) greater than 300 μ m, and wherein the subject has been previously administered a corticosteroid for at least three months,
- 10 wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and wherein the antibody is formulated for subcutaneous administration at a dose from 150 mg to 200 mg once every two weeks.
- 15 2. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of macular edema in a subject in need thereof, in combination with a corticosteroid or corticosteroid tapering, the pharmaceutical composition comprising an antibody that specifically binds IL-6 receptor,
- wherein the subject has a central retinal thickness (CRT) greater than 300 μ m, and
- 20 wherein the subject has been previously administered a corticosteroid for at least three months,
- wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and wherein the antibody is formulated for
- 25 subcutaneous administration at a dose from 150 mg to 200 mg once every two weeks.
3. The use of claim 2, wherein the subject has at least one symptom of macular edema selected from: ocular inflammation, impaired vision, impaired color recognition, tissue thickening, and leakage of ocular vessels, or wherein the macular edema is
- 30 secondary to uveitis.
4. The use of any one of claims 1-3, wherein the subject who has been previously administered the corticosteroid for at least three months is a subject who has been previously administered prednisone for at least three months.

5. The use of claim 4, wherein the prednisone was administered at a dose of from 15 mg/day to 80 mg/day.
- 5 6. The use of any one of claims 1-5, wherein the subject has also been previously administered methotrexate.
7. The use of any one of claims 1-6, wherein the corticosteroid or corticosteroid tapering comprises prednisone or prednisone tapering.
- 10 8. The use of any one of claims 1-7, in combination with the corticosteroid or the corticosteroid tapering and methotrexate.
9. The use of any one of claims 1-8, wherein the subject achieves after at least 16 weeks of the treatment an improvement in best corrected visual acuity (BCVA).
- 15 10. The use of any one of claims 1-8, wherein the subject achieves after at least 16 weeks of the treatment a reduction in the CRT.
11. The use of any one of claims 1-8, wherein the subject achieves after at least 16 weeks of the treatment an improvement in retinal vessel leakage.
- 20 12. The use of any one of claims 1-8, wherein the subject achieves after at least 52 weeks of the treatment an improvement in BCVA, a reduction in the CRT, or an improvement in retinal vessel leakage.
- 25 13. The use of any one of claims 1-8, wherein the subject achieves after at least 52 weeks of the treatment a reduction in the VH level on the Miami 9 point scale of at least 2 steps or a reduction of corticosteroid dose to less than a prednisone-equivalent dose of 10 mg per day.
- 30

14. The use of any one of claims 1-13, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 4 and a light chain comprising the amino acid sequence of SEQ ID NO: 5.

5 15. The use of any of claims 1-13, wherein the antibody is sarilumab.

16. The use of any of claims 1-15, wherein the antibody is formulated for subcutaneous administration at a dose of 200 mg once every two weeks.

10